AMC Health Partners with Icahn School of Medicine on Televideo-Enabled Prostate Cancer Clinical Trial
Technology Provides Access to Patients Living Far from Study Site
Today, AMC Health announced the first patient enrolled in a prostate cancer clinical trial deploying televideo, at Mount Sinai's Icahn School of Medicine in Manhattan. The trial is testing whether the antidiabetic medication metformin may slow the progression of recurrent prostate cancer. AMC Health, a leading provider of proven mobile health solutions, has pioneered the use of televideo in clinical trials and is providing this capability for the study.
Matthew Galsky, M.D., Associate Professor of Medicine at Icahn School of Medicine, Director of Genitourinary Medical Oncology at Tisch Cancer Center at Mount Sinai and the principal investigator, said, "Our prior research demonstrates that geographic barriers and travel burdens prevent many patients from participating in clinical trials. This televideo technology by AMC Health provides a solution, connecting patients remotely with our study site. Patients living at great distances from Mount Sinai may come for an initial visit, but may be unable to travel monthly for follow-up visits, preventing them from participating in clinical trials. 'Video visits' make their participation possible."
The protocol for the trial was developed with input from patients, physicians and researchers, using an innovative crowd-sourcing platform developed by Transparency Life Sciences, a New York-based open-source pharmaceutical development company. "I developed a draft protocol," Dr. Galsky explained, "and 'the crowd' used Transparency's Internet platform to make significant improvements to the trial design."
"This study introduces innovative technologies that can improve future clinical trials," according to John Holland, Senior VP for Research in the Clinical Trials Division of AMC Health, "and we are honored to partner with Dr. Galsky and Mount Sinai in this effort."
Tweet This: Innovative #ClinicalTrial creates possible new treatment for prostate #cancer |http://bit.ly/1tE5k7o @AMCHealth @MountSinaiNYC #telehealth
Truqap Combination Shines in Phase III Trial for Prostate Cancer
November 26th 2024Data from the CAPItello-281 trial show Truqap alongside abiraterone and androgen deprivation therapy achieved a statistically significant and clinically meaningful improvement in radiographic progression-free survival.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
